Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

13.87
+0.61004.60%
Post-market: 14.000.1300+0.94%16:53 EDT
Volume:6.45M
Turnover:88.67M
Market Cap:1.90B
PE:-3.64
High:14.07
Open:13.31
Low:13.31
Close:13.26
52wk High:28.25
52wk Low:6.83
Shares:137.00M
Float Shares:131.00M
Volume Ratio:0.36
T/O Rate:4.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8100
EPS(LYR):-3.8100
ROE:-53.48%
ROA:-27.11%
PB:2.83
PE(LYR):-3.64

Loading ...

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

TIPRANKS
·
May 02

Intellia awards 208,850 inducement RSUs to 43 new employees under 2024 plan

Reuters
·
May 02

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
May 02

Intellia Therapeutics Prices Public Equity Offering to Fund Pipeline

TIPRANKS
·
May 01

Intellia Therapeutics announces annual shareholder meeting notice

Reuters
·
May 01

Stock Track | Intellia Therapeutics Soars 5.02% Intraday as Cathie Wood's ARK Investment Buys 2.4M Shares

Stock Track
·
Apr 30

Lexeo Therapeutics appoints Laura Sepp-Lorenzino to board

Reuters
·
Apr 30

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

TIPRANKS
·
Apr 30

BUZZ-U.S. STOCKS ON THE MOVE-Seagate, GE Healthcare, Bloom Energy

Reuters
·
Apr 30

BUZZ-Gene-editing firm Intellia falls on $180 mln stock sale

Reuters
·
Apr 29

Stock Track | Intellia Therapeutics Plunges 5.23% in Pre-market Despite Positive Phase 3 Results Amid Equity Offering

Stock Track
·
Apr 29

Intellia prices 16,744,187-share follow-on offering at USD 10.75 each

Reuters
·
Apr 29

Intellia Therapeutics Inc - Public Offering Price Set at $10.75 per Share

THOMSON REUTERS
·
Apr 29

Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing

Simply Wall St.
·
Apr 29

Stock Track | Intellia Therapeutics Soars 5.06% Intraday on Multiple Analyst Upgrades and ARK Invest Buying

Stock Track
·
Apr 28

Chardan Lifts Price Target on Intellia Therapeutics to $30 From $27, Keeps Buy Rating

MT Newswires Live
·
Apr 28

Intellia Therapeutics price target raised to $30 from $28 at Citizens

TIPRANKS
·
Apr 28

Intellia Therapeutics Inc : Canaccord Genuity Raises Target Price to $58 From $48

THOMSON REUTERS
·
Apr 28

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

TIPRANKS
·
Apr 28

Intellia Therapeutics Inc : Leerink Partners Raises Target Price to $35 From $29

THOMSON REUTERS
·
Apr 28